A5013156684- Vasculitis and related conditions
- Rheumatoid Arthritis Research and Therapies
- Systemic Lupus Erythematosus Research
- Monoclonal and Polyclonal Antibodies Research
- Coagulation, Bradykinin, Polyphosphates, and Angioedema
- T-cell and B-cell Immunology
- Chronic Lymphocytic Leukemia Research
- Autoimmune and Inflammatory Disorders Research
- Sarcoidosis and Beryllium Toxicity Research
- Cell Adhesion Molecules Research
- Salivary Gland Disorders and Functions
- Otitis Media and Relapsing Polychondritis
- Systemic Sclerosis and Related Diseases
- Immune Cell Function and Interaction
- Lymphoma Diagnosis and Treatment
- Heparin-Induced Thrombocytopenia and Thrombosis
- Renal Diseases and Glomerulopathies
- Immunodeficiency and Autoimmune Disorders
- Atherosclerosis and Cardiovascular Diseases
- Diabetes and associated disorders
- Urticaria and Related Conditions
- Cytokine Signaling Pathways and Interactions
- Salivary Gland Tumors Diagnosis and Treatment
- Immunotherapy and Immune Responses
- Neutrophil, Myeloperoxidase and Oxidative Mechanisms
Duke Medical Center
2014-2024
Duke University
2015-2024
Boston University
2005-2021
University of Michigan
2005-2021
Immune Tolerance Network
2006-2021
Duke University Hospital
2003-2021
Brigham and Women's Hospital
2006-2021
University of California, Los Angeles
2006-2021
University of Pennsylvania
2006-2021
Rho (United States)
2021
Neutralization of tumor necrosis factor α (TNF-α) for three to six months reduces the symptoms and signs rheumatoid arthritis. However, capacity this approach effect a more sustained benefit its on joint damage are not known.
Cyclophosphamide and glucocorticoids have been the cornerstone of remission-induction therapy for severe antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis 40 years. Uncontrolled studies suggest that rituximab is effective may be safer than a cyclophosphamide-based regimen.
Abstract Objective To compare the benefits of initiating treatment with methotrexate (MTX) and infliximab (anti–tumor necrosis factor α [anti‐TNFα] monoclonal antibody) those MTX alone in patients rheumatoid arthritis (RA) ≤3 years' duration. Methods RA were eligible if they had active disease no prior or a TNFα inhibitor. One thousand forty‐nine randomly assigned 4:5:5 ratio to 3 groups: MTX–placebo, MTX–3 mg/kg infliximab, MTX–6 infliximab. dosages rapidly escalated 20 mg/week, placebo...
The design of a human immunodeficiency virus-1 (HIV-1) immunogen that can induce broadly reactive neutralizing antibodies is major goal HIV-1 vaccine development. Although rare monoclonal (mAbs) exist neutralize HIV-1, envelope immunogens do not these antibody specificities. Here we demonstrate the two most gp41 mAbs, 2F5 and 4E10, are polyspecific autoantibodies with phospholipid cardiolipin. Thus, current vaccines may types because autoantigen mimicry conserved membrane-proximal epitopes...
The 18-month efficacy of a single course rituximab as compared with conventional immunosuppression cyclophosphamide followed by azathioprine in patients severe (organ-threatening) antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis is unknown.
Abstract Objective To evaluate the efficacy and safety of repeated administration infliximab plus methotrexate (MTX) over a 2‐year period in patients with rheumatoid arthritis (RA) who previously experienced an incomplete response to MTX. Methods Four hundred twenty‐eight were randomly assigned receive MTX placebo or at dose 3 10 mg/kg for 54 weeks, additional year followup. The protocol was later amended allow continued treatment during second year. Of 259 entered treatment, 216 102 weeks....
Despite current therapies, diffuse cutaneous systemic sclerosis (scleroderma) often has a devastating outcome. We compared myeloablative CD34+ selected autologous hematopoietic stem-cell transplantation with immunosuppression by means of 12 monthly infusions cyclophosphamide in patients scleroderma.
Abstract Objective To identify disease characteristics leading to progression of joint damage in patients with early rheumatoid arthritis (RA) treated methotrexate (MTX) versus those infliximab plus MTX. Methods Patients who had not previously been MTX active RA were randomly assigned receive escalating doses up 20 mg/week placebo or at weeks 0, 2, and 6, every 8 thereafter through week 46. Radiographic was assessed using the modified Sharp/van der Heijde score (SHS). The relationship...
To refine and validate the Birmingham Vasculitis Activity Score (BVAS) as a disease-specific activity index for Wegener's granulomatosis (WG).Sixteen members of International Network Study Systemic Vasculitides (INSSYS) revised BVAS, with 3 goals: to reduce redundancy some component items, enhance its ability capture important disease manifestations specific WG, streamline instrument use in clinical research. We defined items weighted them empirically either minor (e.g., nasal crusting = 1...
Abstract Objective To investigate the relationship between serum concentrations of infliximab, a monoclonal anti–tumor necrosis factor α antibody, and clinical improvement from infliximab therapy for rheumatoid arthritis (RA). Methods Multiple blood samples were obtained each 428 subjects with active RA who enrolled in multicenter, randomized, double‐blind, placebo‐controlled trial (ATTRACT [Anti–Tumor Necrosis Factor Trial Rheumatoid Arthritis Concomitant Therapy]) evaluating efficacy...
To assess whether it is better to intensively treat all patients with early rheumatoid arthritis (RA) using combinations of drugs or reserve this approach for who do not have an appropriate response (as determined by a Disease Activity Score in 28 joints the erythrocyte sedimentation rate [DAS28-ESR] ≥ 3.2 at week 24) methotrexate (MTX) monotherapy, and combination therapy MTX plus etanercept superior sulfasalazine hydroxychloroquine.The Treatment Early Aggressive Rheumatoid Arthritis (TEAR)...
Objective To evaluate whether the classification of patients with anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) according to ANCA type (anti-proteinase 3 (PR3) or anti-myeloperoxidase (MPO) antibodies) predicts treatment response. Methods Treatment responses were assessed among enrolled in Rituximab ANCA-associated Vasculitis trial both AAV diagnosis (granulomatosis polyangiitis (GPA)/microscopic (MPA)) and (PR3-AAV/MPO-AAV). Complete remission (CR) was defined as...
Venous thrombotic events (VTEs) have been observed in Wegener granulomatosis, but the incidence rate is not known.To measure of VTEs patients with granulomatosis.Prospective, observational cohort study.A multicenter, randomized, double-blind, placebo-controlled treatment trial for granulomatosis.180 granulomatosis enrolled during periods active disease.Venous (deep venous thromboses or pulmonary emboli) were documented and confirmed prospectively. Incidence rates calculated on basis time to...
Background: The utility of antineutrophil cytoplasmic antibody (ANCA) levels to guide the management patients with Wegener granulomatosis remains controversial. Objective: To determine whether pro-proteinase 3 (PR3)–ANCA are a better measure disease activity than mature-PR3–ANCA levels, decreases in either level associated shorter time remission, and increases followed by relapse. Design: Prospective, observational cohort study. Setting: 8 United States medical centers that participated...